Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Diamedica Therapeutics ( (DMAC) ) is now available.
DiaMedica Therapeutics announced its financial results for the first quarter of 2025, highlighting ongoing clinical developments. The company is progressing with its Phase 2 trials for DM199 in preeclampsia and acute ischemic stroke, with significant milestones expected soon. The announcement indicates a stable financial position with a cash runway extending into the third quarter of 2026, suggesting a strong operational outlook.
The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, focused on developing novel treatments for acute ischemic stroke and preeclampsia.
Average Trading Volume: 93,697
Technical Sentiment Signal: Sell
Current Market Cap: $163.9M
For detailed information about DMAC stock, go to TipRanks’ Stock Analysis page.